Budesonide Inhaler Market Report 2026

The budesonide inhaler market size has grown strongly in recent years. It will grow from $6.88 billion in 2025 to $7.45 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to asthma prevalence growth, COPD diagnosis rates, corticosteroid inhaler adoption, hospital respiratory care expansion, smoking-related respiratory disorders.

The budesonide inhaler market size is expected to see strong growth in the next few years. It will grow to $10.25 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to chronic respiratory disease burden, smart inhaler development, outpatient respiratory care growth, preventive asthma management, emerging market demand. Major trends in the forecast period include rising demand for long-term respiratory control, increased adoption of combination inhalers, growth in homecare respiratory management, expansion of pediatric and geriatric usage, focus on improved inhaler delivery efficiency.

The increasing prevalence of respiratory disorders is expected to drive the growth of the budesonide inhaler market in the coming years. Respiratory disorders are medical conditions affecting the lungs and airways, causing difficulty in breathing and symptoms such as coughing, wheezing, and shortness of breath. These include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and other lung infections. The rise in respiratory disorders is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and impair lung function. Budesonide inhalers help manage these conditions by delivering anti-inflammatory medication directly to the lungs, providing long-term control. Their compact design allows for easy use and portability, helping to reduce flare-ups and improve respiratory health. For example, in June 2025, Public Health Wales, a UK-based National Health Service organization, projected that the number of patients on asthma and COPD registers in Wales will increase over the next decade. Asthma cases are expected to rise from 237,400 in 2023-24 to over 256,000, while COPD cases are projected to grow from 75,600 to over 84,000. Consequently, the rising prevalence of respiratory disorders is fueling growth in the budesonide inhaler market.

Leading companies in the budesonide inhaler market are focusing on developing innovative solutions, such as generic products, to improve affordability and expand access to respiratory treatments. Generic inhalation products are non-branded versions of inhaled medications that provide the same active ingredients, dosage, and therapeutic effects as their branded equivalents, usually at a lower cost. For example, in July 2023, Viatris Inc., a US-based pharmaceutical company, in collaboration with Kindeva Drug Delivery L.P., a US-based manufacturer, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first FDA-approved generic version of Symbicort. This drug-device combination is intended to treat asthma and chronic obstructive pulmonary disease (COPD) by reducing airway inflammation with budesonide and relaxing airway muscles with formoterol, offering patients a more affordable treatment option.

In January 2025, Molex, a US-based electronics company, acquired Vectura Group Ltd. for an undisclosed amount. Through this acquisition, Molex aims to strengthen its capabilities in medical and inhalation drug delivery by combining Phillips Medisize’s manufacturing expertise with Vectura’s specialization in inhalation devices and formulation development, enhancing its ability to provide innovative therapies for respiratory conditions. Vectura Group, based in the UK, specializes in developing inhalation drug delivery systems, including devices designed to deliver budesonide.

Major companies operating in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.

North America was the largest region in the budesonide inhaler market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the budesonide inhaler market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the budesonide inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the budesonide inhaler market by increasing the cost of imported active pharmaceutical ingredients, propellants, and inhaler device components. These impacts have been most pronounced in metered-dose and combination inhaler segments, particularly in north america and europe where device manufacturing relies on global suppliers. Asia-pacific producers have faced component sourcing challenges. However, tariffs have encouraged domestic inhaler manufacturing and device localization.

The budesonide inhaler market research report is one of a series of new reports that provides budesonide inhaler market statistics, including budesonide inhaler industry global market size, regional shares, competitors with a budesonide inhaler market share, detailed budesonide inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the budesonide inhaler industry. This budesonide inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Budesonide inhaler is a respiratory device that delivers the corticosteroid budesonide directly to the lungs, helping to reduce airway inflammation and improve breathing. It is prescribed for the long-term management of respiratory conditions.

The main product types in the budesonide inhaler market include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and combination inhalers. MDIs are handheld devices that deliver a precise dose of medication as a short burst of aerosol directly to the lungs. Dosage forms include aerosols, dry powders, suspensions, and sprays, indicated for conditions such as asthma, chronic obstructive pulmonary disease, and allergic rhinitis. End users include hospitals, outpatient clinics, homecare settings, and pharmacies.

The budesonide inhaler market consists of sales of soft mist inhalers, nasal inhalers, budesonide repulse, oral inhalation capsules, and transdermal inhalation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.